Pfizer Secures Global Rights to Fosun Pharma’s Oral GLP-1 Program

Pfizer Secures Global Rights to Fosun Pharma’s Oral GLP-1 Program

By, Admin 12 December 2025

China’s Fosun Pharma has signed a major collaboration and licensing deal with Pfizer, marking a significant move in the competitive metabolic-disease market. The agreement centers on oral small-molecule GLP-1 receptor agonists, including YP05002, a next-generation candidate designed for chronic weight management and metabolic disorders.

A High-Value Global Licensing Agreement

Under the deal, Fosun’s subsidiary Yao Pharma will grant Pfizer an exclusive worldwide license to develop, manufacture, and commercialize its oral GLP-1R agonists.

Key terms include:

  • $150 million upfront payment to Yao Pharma
  • Up to $1.935 billion in development, regulatory, and commercial milestone payments
  • Tiered royalties on future global sales
  • Coverage across all therapeutic, diagnostic, and prophylactic indications for both human and veterinary use

This structure positions the agreement as one of the larger oral-GLP-1 licensing deals in recent years.

YP05002: A Growing Contender in the GLP-1 Space

YP05002 and related oral GLP-1R agonists were fully developed by Yao Pharma and carry proprietary intellectual property rights. These assets target a fast-expanding market driven by rising obesity and type 2 diabetes rates.

Potential indications include:

  • Chronic weight management
  • Type 2 diabetes
  • Metabolic dysfunction-associated steatohepatitis (MASH / NASH)
  • Other metabolic diseases

Yao Pharma will continue its ongoing Phase 1 trial in Australia, after which Pfizer takes full control of global development and commercialization.

Why This Deal Matters?

The global GLP-1 market is undergoing rapid transformation. Oral small-molecule GLP-1 drugs represent the next wave of innovation because they:

  • Offer easier administration than injectables
  • Could reduce manufacturing complexity
  • May support broader patient adoption

Pfizer’s move signals its intent to strengthen its metabolic-disease portfolio after earlier setbacks in its obesity pipeline.

What It Means for the Industry?

This partnership reflects a rising trend: global pharma companies are aggressively acquiring oral GLP-1 candidates to secure a place in one of the most competitive drug markets of the decade.

For Fosun Pharma, the deal validates years of internal R&D and positions its small-molecule GLP-1 platform on the global stage.

For Pfizer, it opens a renewed path back into obesity and diabetes therapeutics—areas expected to exceed $100 billion in annual revenue by 2030.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!